Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Pediatrix Medical (MD) over the last 17 years, with Q3 2025 value amounting to $340.1 million.

  • Pediatrix Medical's Cash & Equivalents rose 22751.2% to $340.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $340.1 million, marking a year-over-year increase of 22751.2%. This contributed to the annual value of $229.9 million for FY2024, which is 21387.7% up from last year.
  • Pediatrix Medical's Cash & Equivalents amounted to $340.1 million in Q3 2025, which was up 22751.2% from $224.7 million recorded in Q2 2025.
  • Pediatrix Medical's 5-year Cash & Equivalents high stood at $387.4 million for Q4 2021, and its period low was $5.8 million during Q2 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $73.3 million (2023), whereas its average is $132.9 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 9757.82% in 2022, then skyrocketed by 113753.44% in 2025.
  • Over the past 5 years, Pediatrix Medical's Cash & Equivalents (Quarter) stood at $387.4 million in 2021, then plummeted by 97.46% to $9.8 million in 2022, then skyrocketed by 645.7% to $73.3 million in 2023, then soared by 213.88% to $229.9 million in 2024, then surged by 47.89% to $340.1 million in 2025.
  • Its Cash & Equivalents stands at $340.1 million for Q3 2025, versus $224.7 million for Q2 2025 and $99.0 million for Q1 2025.